Conditions: Candidates for Systemic Therapy for Psoriasis Psoriasis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 189
Healthy volunteers: no

Brief summary:
An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Efalizumab
Intervention descriptions: intervention 1: Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.

Protocol document: